Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
99.94
+3.23 (3.34%)
At close: May 12, 2026, 4:00 PM EDT
100.02
+0.08 (0.08%)
After-hours: May 12, 2026, 7:57 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $301.67M in the quarter ending March 31, 2026, with 48.26% growth. This brings the company's revenue in the last twelve months to $1.08B, up 39.56% year-over-year. In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth.
Revenue (ttm)
$1.08B
Revenue Growth
+39.56%
P/S Ratio
12.27
Revenue / Employee
$431,051
Employees
2,506
Market Cap
13.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.63B |
| Labcorp Holdings | 14.14B |
| Quest Diagnostics | 11.28B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.39B |
| Mettler-Toledo International | 4.09B |
| Charles River Laboratories International | 4.03B |
| Revvity | 2.90B |
GH News
- 10 hours ago - Guardant Health Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 16 hours ago - Guardant Health price target raised to $135 from $130 at Piper Sandler - TheFly
- 4 days ago - Guardant Health price target raised to $95 from $90 at Evercore ISI - TheFly
- 4 days ago - Guardant Health price target raised to $129 from $120 at Baird - TheFly
- 4 days ago - Guardant Health price target raised to $135 from $130 at JPMorgan - TheFly
- 4 days ago - Guardant Health price target raised to $120 from $115 at Barclays - TheFly
- 5 days ago - Guardant Health reports Q1 adjusted EPS (45c), consensus (47c) - TheFly
- 5 days ago - Guardant Health raises FY26 revenue view to $1.3B-$1.32B from $1.25B-$1.28B - TheFly